Antibody In-Vivo Protein Reagent 
Drug Discovery World
APRIL 3, 2023
DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale? I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.
Drug Discovery World
OCTOBER 13, 2022
Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
DECEMBER 13, 2023
In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools. This article is sponsored by Fortis Life Sciences.
Drug Discovery World
NOVEMBER 30, 2023
The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It GSK has developed high-throughput mammalian and E.
XTalks
APRIL 22, 2022
Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.
Drug Discovery World
JULY 18, 2023
Current research is focused on designing CRISPR-enhanced CAR T cells that are resistant to immunosuppressive cytokines such as transforming growth factor-β (TGF-β) 2 , programmed cell death protein (PD-1) 3 , or other negative T cell regulators 4 (CTLA-4, LAG-3, and TIM-3), thus improving anti-tumour functions.
Drug Discovery World
OCTOBER 20, 2022
Fibroblasts in the tumour microenvironment. Cancer associated fibroblasts (CAFs) have recently emerged as key players in the tumour microenvironment. Since CAFs are a type of fibroblast, the most common cell type in connective tissue, they play critical roles in the production of extracellular matrix and stroma. Spectral flow cytometry.
Expert insights. Personalized for you.
52 
Let's personalize your content